×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVBP – arrivent biopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVBP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
05:45 pm
avbp
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]
3/17
05:34 pm
avbp
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]
Medium
Report
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]
3/17
05:00 pm
avbp
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
Medium
Report
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
3/17
05:00 pm
avbp
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Medium
Report
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
3/14
06:58 am
avbp
ArriVent BioPharma (AVBP) was upgraded by BTIG Research to "strong-buy".
Low
Report
ArriVent BioPharma (AVBP) was upgraded by BTIG Research to "strong-buy".
3/12
08:03 am
avbp
ArriVent BioPharma (AVBP) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Low
Report
ArriVent BioPharma (AVBP) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
3/11
02:18 pm
avbp
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
3/6
12:25 pm
avbp
ArriVent BioPharma (AVBP) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock, up from $44.00.
Medium
Report
ArriVent BioPharma (AVBP) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock, up from $44.00.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/17
05:05 pm
avbp
Form 8-K ArriVent BioPharma, Inc. For: Mar 17
Medium
Report
Form 8-K ArriVent BioPharma, Inc. For: Mar 17
3/5
04:24 pm
avbp
Form S-8 ArriVent BioPharma, Inc.
Medium
Report
Form S-8 ArriVent BioPharma, Inc.
3/5
04:18 pm
avbp
Form 10-K ArriVent BioPharma, Inc. For: Dec 31
Medium
Report
Form 10-K ArriVent BioPharma, Inc. For: Dec 31
3/5
04:12 pm
avbp
Form 8-K ArriVent BioPharma, Inc. For: Mar 05
Medium
Report
Form 8-K ArriVent BioPharma, Inc. For: Mar 05
3/5
06:09 am
avbp
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners IX, L.P.
Medium
Report
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners IX, L.P.
2/17
04:36 pm
avbp
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: INFINITUM ASSET MANAGEMENT, LLC
Low
Report
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: INFINITUM ASSET MANAGEMENT, LLC
2/17
09:01 am
avbp
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Low
Report
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: HILLHOUSE INVESTMENT MANAGEMENT, LTD.
2/4
08:44 pm
avbp
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: LaChapelle Robin
Medium
Report
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: LaChapelle Robin
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: